

IN THE CLAIMS:

Please amend claims 55 and 70 as indicated below. Please cancel claims 61 and 76. In compliance with 37 C.F.R. § 1.121, a complete listing of the claims is presented below. For currently amended claims deleted language is shown by strikethrough or brackets and added language is shown by underlining. No new matter has been added.

Claims 1-54 (cancelled)

55. (currently amended) A pharmaceutical composition for the treatment of a vascular disease or condition selected from the group consisting of atherosclerosis, hyperlipidemia, and hypoalphalipoproteinemia in a human, comprising a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes ~~free of drug~~ having empty aqueous cores and having a Gaussian distribution wherein at least 68% of the liposomes have a mean diameter of about 125 ± 30 nm, which liposomes mobilize more cholesterol than an equal amount of unilamellar phospholipid liposomes having a mean diameter of 30 ± 7 nm as measured in mice.

56. (previously presented) The pharmaceutical composition of claim 55 wherein 68% of the liposomes have a mean diameter between about 100-150 nm.

57. (currently amended) The pharmaceutical composition of claim 55 in which the therapeutically effective amount is about 0.1-1.5 ~~gm/kg~~ grams per kilogram body weight.

58. (currently amended) The pharmaceutical composition of claim 55 in which the therapeutically effective amount is about 0.28-0.42 ~~gm/kg~~ grams per kilogram body weight.

59. (previously presented) The pharmaceutical composition of claim 55 in which the therapeutically effective amount is about 300 mg per kg body weight.

60. (previously presented) The pharmaceutical composition of claim 55 comprising a pharmaceutically acceptable carrier selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution.

61. (canceled)

62. (previously presented) The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is in the range of about 20-200 mg/ml.

63. (previously presented) The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is about 200 mg/ml.

64. (previously presented) The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is in the range of about 50-150 mg/ml.

65. (previously presented) The pharmaceutical composition of claim 60 wherein the concentration of liposomes in the carrier is about 100 mg/ml.

66. (previously presented) The pharmaceutical composition of claim 55 wherein the composition is lyophilized.

67. (previously presented) The pharmaceutical composition of claim 55, wherein the phospholipid is selected from the group consisting of egg phosphatidylcholine, egg phosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, lecithin, β,γ -dipalmitoyl- α -lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, oleoyl-palmitoyl-phosphatidylcholine, dioleoylphosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myristoyl-phosphatidylserine, and mixtures thereof.

68. (previously presented) The pharmaceutical composition of claim 55, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, and mixtures thereof.

69. (previously presented) The pharmaceutical composition of claim 55, wherein the phospholipids are in a liquid crystalline phase at about 37°C.

70. (currently amended) A pharmaceutical composition for the treatment of a vascular disease or condition selected from the group consisting of atherosclerosis, hyperlipidemia, and hypoalphalipoproteinemia in a human, comprising a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes free of drug having empty aqueous cores which liposomes are effective in promoting cholesterol efflux without causing a substantial increase in LDL or esterified cholesterol levels.

71. (previously presented) The pharmaceutical composition of claim 70 wherein the liposomes have a mean diameter between about 100-150 nm.

72. (currently amended) The pharmaceutical composition of claim 70 in which the therapeutically effective amount is about 0.1-1.5 gm/kg grams per kilogram body weight.

73. (currently amended) The pharmaceutical composition of claim 70 in which the therapeutically effective amount is about 0.28-0.42 gm/kg grams per kilogram body weight.

74. (previously presented) The pharmaceutical composition of claim 70 in which the therapeutically effective amount is about 300 mg per kg body weight.

75. (previously presented) The pharmaceutical composition of claim 70 comprising a pharmaceutically acceptable carrier selected from the group consisting of sterilized water, sterilized buffered water, sterilized saline solution, and a sterilized aqueous solution.

76. (canceled)

77. (previously presented) The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is in the range of about 20-200 mg/ml.

78. (previously presented) The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is about 200 mg/ml.

79. (previously presented) The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is in the range of about 50-150 mg/ml.

80. (previously presented) The pharmaceutical composition of claim 75 wherein the concentration of liposomes in the carrier is about 100 mg/ml.

81. (previously presented) The pharmaceutical composition of claim 70 wherein the composition is lyophilized.

82. (previously presented) The pharmaceutical composition of claim 70, wherein the phospholipid is selected from the group consisting of egg phosphatidylcholine, egg phosphatidylglycerol, distearoylphosphatidylcholine, distearoylphosphatidylglycerol, phosphatidylcholine, phosphatidylglycerol, lecithin, β,γ -dipalmitoyl- α -lecithin, sphingomyelin, phosphatidylserine, phosphatidic acid, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylinositol, cephalin, cardiolipin, oleoyl-palmitoyl-phosphatidylcholine, dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, dioleoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylcholine, di-stearoyl-phosphatidylcholine, stearoyl-palmitoyl-phosphatidylcholine, di-palmitoyl-phosphatidylethanolamine, di-stearoyl-phosphatidylethanolamine, di-myristoyl-phosphatidylserine, and mixtures thereof.

83. (previously presented) The pharmaceutical composition of claim 70, wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, and mixtures thereof.

84. (previously presented) The pharmaceutical composition of claim 70, wherein the phospholipids are in a liquid crystalline phase at about 37°C.